Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT

List view / Grid view

Manufacturing

 

Lonza logo with background
Lonza logo with background
news

Beat In-Albon new COO of the life science ingredients sector

1 June 2012 | By

Starting on 1 June 2012, Beat In-Albon will join Lonza as COO of the Life Science Ingredients Sector and become a member of the Management Committee, replacing Harry Boot. Beat In-Albon brings broad industry experience to his role, having worked for Lonza already from 1983-2006, where he was Head of…

Implementing chemometrics in late stage development and manufacturing
Implementing chemometrics in late stage development and manufacturing
article

Implementing chemometrics in late stage development and manufacturing

26 April 2012 | By Geir Rune Flåten, former Chemometrician Leader in Global Manufacturing and Supply at GlaxoSmithKline

Chemometrics was defined as a research area in 1974 and developed rapidly through the following decades in parallel with the fast paced improvement in analytical technologies and computational power for lab instruments and sensors. Chemometrics is essentially the translation of measured signals characterising a sample or a process into meaningful…

article

Discovery chemistry outsourcing

26 April 2012 | By Luigi La Vecchia, Director of the Preparations Laboratories, Novartis Institute for Biomedical Research

In 2002, Novartis decided to create a new research centre in Cambridge, MA. This was accompanied by a significant increase in headcount in medicinal chemistry. Within two years, this resulted in a strongly increased demand for prep-scale synthesis which in turn led to priority issues and to prolonged turnaround times…

article

Outsourcing in early drug discovery: Evolution and opportunities

26 April 2012 | By Jayshree Mistry, Paul Lloyd, Kevin Oliver and Peter North, GlaxoSmithKline R&D and Duncan Judd, Awridian

This article describes the evolution of outsourcing within early drug discovery at GlaxoSmithKline (GSK), specifically for chemistry services applied to developing a compound from the screening hit through lead optimisation. It will touch on different business models, factors to consider when selecting potential CROs, the benefits of outsourcing and CRO…

Article 3: The implementation of rapid microbiological methods
Article 3: The implementation of rapid microbiological methods
article

Rapid micro methods and EMA’s post approval change management protocol

26 April 2012 | By Michael J. Miller, President, Microbiology Consultants, LLC

This is the second paper in our continuing series on Rapid Microbiological Methods that will appear in European Pharmaceutical Review during 2012. In my last article, we discussed a number of myths or misconceptions associated with the validation and implementation of rapid microbiological methods (RMMs). In fact, most RMM myths…

HEOS by SCYNEXIS
HEOS by SCYNEXIS
product

HEOS® by SCYNEXIS

9 March 2012 | By Accelrys

Learn more about HEOS® by SCYNEXIS - a SaaS workspace in which multiple, disparate companies, academic collaborators or CROs can exchange scientific data securely and in real-time.

article

New year, old challenges!

28 February 2012 | By Michael J. Miller, President, Microbiology Consultants, LLC

This is the first of many articles in our continuing series on Rapid Microbiological Methods that will appear in European Pharmaceutical Review during 2012. For the past two years, I have enjoyed sharing with you a broad range of topics associated with the validation and implementation of rapid microbiological methods…